Business
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans
About this update from Aligos Therapeutics, Inc.
[{"type":"text","content":"Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans following positive feedback from the FDA to move forward with chronic HBV DNA suppression as the primary efficacy endpointScheduled for Thursday, July 18, 2024 at 3:00pm ET/12:00pm PT SOUTH SAN FRANCISCO, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Johns Hopkins University School of Medicine, to discuss the unmet need and current treatment landscape for patients with chronic hepatitis B (CHB), positive data from the Phase 1b study of ALG-000184, development plans, and the chronic suppression regulatory pathway on Thursday, July 18, 2024 at 3:00pm ET/12:00pm PT. “We are pleased to be hosting this KOL event with Dr. Sulkowski, as we are excited to share the recent FDA feedback on the path forward to bring our best/first-in-class molecule to patients in need of better therapies,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “ALG-000184 monotherapy continues to show unprecedented reductions in all viral markers of CHB without viral breakthrough, with data 72 weeks that was recently presented at the EASL Congress 2024. The efficacy data to date has already demonstrated the potential for superiority compared to nucleos(t)ide analogs, reducing HBV DNA levels below 10 IU/mL in both HBeAg-positive and HBeAg-negative patients at Week 48. We look forward to providing additional details on the chronic suppression indication during the event.” Mark Sulkowski, MD, is a Professor of Medicine, the Senior Associate Dean for Clinical Trials, and the Founding Director of the Office of Clinical Trials at the Johns Hopkins University School of Medicine. He also serves as the Director of the Division of Infectious Diseases at the Johns Hopkins Bayview Medical Center, a Deputy Director for the Johns Hopkins Institute for Clinical and Translational Research, and the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroe...